LMF Acquisition Opportunity Renamed SeaStar Medical Holding Corporation
Seastar Medical Holding Corporation Common Stock and Stock Acquisition Rights Begin Trading on the Nasdaq under New Ticker Symbols “ICU” and “ICUCW”
DENVER & TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) — SeaStar Medical, Inc., a medical technology company developing unique solutions to reduce the effects of hyper-inflammation on vital organs, earlier today announced announced a business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special-purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA). The business combination was completed on October 28, 2022.
Upon completion of the business combination, LMF Acquisition Opportunities, Inc. will be renamed SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, led by CEO Eric Schlorff. Caryl Baron will serve as interim CFO. SeaStar Medical Holding Corporation’s common stock and stock acquisition rights are expected to begin trading on October 31, 2022 on the Nasdaq under the new ticker symbols “ICU” and “ICUCW.”
The transaction was unanimously approved by the boards of directors of both SeaStar Medical and LMAO. Majority holders of SeaStar Medical’s voting rights have approved the merger. LMAO shareholders approved the transaction at a special meeting of his LMAO shareholders on October 18, 2022, with over 96% of the votes cast supporting the transaction.
Eric Schkrolf, President and Chief Executive Officer of Seastar Medical Holding Corporation, said: The deal provides more resources to advance selective cell transplantation devices (SCDs) for patients suffering from the devastating consequences of hyperinflammation. We have submitted a Humane Medical Device Exemption (HDE) application for pediatric use to the US Food and Drug Administration (FDA). 2023. As a public company, we are better positioned to advance these programs. “
Bruce M. Rodgers, Chairman and CEO of LM Funding, sponsor of LMF Acquisition Opportunities, commented: We are very pleased with the overwhelming support of the shareholders of the LMF acquisition and believe this transaction will deliver significant value to the shareholders of LM Funding and SeaStar Medical. As a public company, Seastar Medical Holding Corporation looks forward to continuing to advance potentially life-saving therapies. “
Maxim Group LLC acted as sole financial advisor and Morgan Lewis & Bockius LLP acted as legal advisor to SeaStar Medical in connection with the business combination. Foley & Lardner LLP acted as legal counsel to LMAO in connection with the business combination. Ellenoff Grossman & Schole LLP acted as legal counsel to Maxim Group LLC.
About Seastar Medical
Denver-based SeaStar Medical is a medical technology company focused on redefining how extracorporeal therapy reduces the effects of excessive inflammation in vital organs. SeaStar Medical’s new technology relies on science and innovation to provide life-saving solutions for critically ill patients. The company develops and commercializes in vitro therapies that target effector cells that promote systemic inflammation, causing direct tissue damage and a range of pro-inflammatory drugs that initiate and propagate an imbalanced immune response. It secretes cytokines. For more information, please visit http://www.seasarmedical.com/ or follow us on LinkedIn or Twitter.
About LM Funding America
LM Funding America, Inc. (Nasdaq: LMFA) and its subsidiaries is a cryptocurrency mining business that began mining Bitcoin in September 2022. The Company also has non-profit community associations (associations) located primarily in Florida, Washington, Colorado, and Illinois that fund certain portions of the association’s rights to delinquent accounts selected by the association from the association’s unpaid valuations. offers.
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. With respect to the proposed business combination between LMAO and SeaStar Medical, the advantages of the transaction, the ability of SeaStar Medical Holding Corporation to deliver value to its stakeholders, the implied valuation of SeaStar Medical, and the statements regarding the products offered by SeaStar Medical Holding Corporation. the markets in which Seastar Medical Holding Corporation operates, including the expected timing of regulatory approvals for Seastar Medical Holding Corporation’s products; “believe”, “plan”, “expect”, “predict”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “could” , “should,” and other words “will,” “will,” “will,” “will continue,” “will probably result,” and similar expressions It is intended to identify forward-looking statements. Forward-looking statements are predictions, forecasts and other statements about future events that are based on current expectations and assumptions and involve significant risks that actual results may differ materially from those anticipated. and uncertainties. Most of these factors are outside the control of LMAO and SeaStar Medical and are difficult to predict. Factors that could cause actual future events to differ materially from projected results include, but are not limited to: the ability of the combined company to grow, manage growth profitability and retain key employees; (ii) costs associated with the business merger; as a result of legal proceedings that may result in (x) the ability to maintain a listing of the securities on the Nasdaq; (iv) the ability to execute business plans, forecasts and other expectations following the completion of the proposed business combination; and (v) The risk of recession and the potential for rapid change in the highly competitive industry in which SeaStar Medical operates. (vi) SeaStar Medical Holding Corporation and its current and future collaborators experience significant delays, including the risk of not being able to successfully develop and commercialize its products or services or obtaining applicable product approvals; risk to do. federal and state regulators; (vii) the risk that SeaStar Medical Holding Corporation may not be able to achieve or maintain profitability; (viii) the risk that SeaStar Medical Holding Corporation may need to raise additional capital to carry out its business plans; Often on acceptable terms or not available at all. (ix) the risk that third party suppliers and manufacturers may fail to fully and timely meet their obligations; (x) the risk of product liability or regulatory litigation or proceedings relating to SeaStar Medical’s products and services; ) The following risks SeaStar Medical Holding Corporation cannot secure or protect its intellectual property. and (xiii) other risks and uncertainties set forth from time to time in the LMAO Registration Statement on Form S-4, as amended (File No. 333-264993). described in its “Risk Factors” section and other documents filed with the SEC by the LMAO. The preceding list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements. Seastar Medical, LMAO and Seastar Medical Holding Corporation undertake no obligation to update or revise these forward-looking statements as a result of new information or future events. event, or otherwise.
Email: [email protected]
SeaStar Medical Investor Contact:
JTC Team, LLC
Phone: (833) 475-8247
Email: [email protected]
LM Funding Investor Contact:
Crescendo Communications, LLC
David Waldman or Ted Ayvas
Email: [email protected]